Is SELDI-TOF a valid tool for diagnostic biomarkers?

Trends in Parasitology

Volumn 26, Issue 12, 2010, Pages 561-567

  Ndao, Momar ^a,c   Rainczuk, Adam ^a   Rioux, Marie Claire ^b   Spithill, Terry W ^b,c,d   Ward, Brian J ^a,c  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d CHARLES STURT UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROTEOME;

AFRICAN TRYPANOSOMIASIS; CHAGAS DISEASE; DISEASE COURSE; DNA DETERMINATION; GENOME; HOST PARASITE INTERACTION; HUMAN; IMMUNOASSAY; INFECTION RESISTANCE; MALARIA; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; PARASITOSIS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SEROLOGY; SHORT SURVEY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TOXOPLASMOSIS; VISCERAL LEISHMANIASIS;

BIOLOGICAL MARKERS; BLOOD BANKS; BLOOD-BORNE PATHOGENS; CHAGAS DISEASE; HOST-PARASITE INTERACTIONS; LEISHMANIASIS, VISCERAL; MALARIA; PROTEOME; PROTOZOAN INFECTIONS; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TOXOPLASMOSIS; TRYPANOSOMIASIS, AFRICAN;

EID: 78149471475     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2010.07.004     Document Type: Short Survey

References (60)

1. Alter H.J., et al. Emerging infectious diseases that threaten the blood supply. Semin. Hematol. 2007, 44:32-41.
2. Bihl F., et al. Transfusion-transmitted infections. J. Transl. Med. 2007, 5:25.
3. Dodd R. Managing the microbiological safety of blood for transfusion: a US perspective. Future Microbiol. 2009, 4:807-818.
4. El Ghouzzi M.H., et al. Testing blood donors for Chagas disease in the Paris area, France: first results after 18 months of screening. Transfusion 2010, 50:575-583.
5. Berrizbeitia M., et al. Field evaluation of four novel enzyme immunoassays for Chagas' disease in Venezuela blood banks: comparison of assays using fixed-epimastigotes, fixed-trypomastigotes or trypomastigote excreted-secreted antigens from two Trypanosoma cruzi strains. Transfus. Med. 2006, 16:419-431.
6. Pirard M., et al. The validity of serologic tests for Trypanosoma cruzi and the effectiveness of transfusional screening strategies in a hyperendemic region. Transfusion 2005, 45:554-561.
7. Leiby D.A., et al. Trypanosoma cruzi in Los Angeles and Miami blood donors: impact of evolving donor demographics on seroprevalence and implications for transfusion transmission. Transfusion 2002, 42:549-555.
8. Steele L.S., et al. The sero-prevalence of antibodies to Trypanosoma cruzi in Latin American refugees and immigrants to Canada. J. Immigr. Minor. Health 2007, 9:43-47.
9. Alves F.P., et al. Asymptomatic carriers of Plasmodium spp. as infection source for malaria vector mosquitoes in the Brazilian Amazon. J. Med. Entomol. 2005, 42:777-779.
10. da Silva N.S., et al. Epidemiology and control of frontier malaria in Brazil: lessons from community-based studies in rural Amazonia. Trans. R. Soc. Trop. Med. Hyg. 2010, 104:343-350.
11. Fugikaha E., et al. Molecular screening of Plasmodium sp. asymptomatic carriers among transfusion centers from Brazilian Amazon region. Rev. Inst. Med. Trop. Sao Paulo 2007, 49:1-4.
12. Ndao M., et al. Comparison of blood smear, antigen detection, and nested-PCR methods for screening refugees from regions where malaria is endemic after a malaria outbreak in Quebec, Canada. J. Clin. Microbiol. 2004, 42:2694-2700.
13. Gay-Andrieu F., et al. Comparative evaluation of the ARCHITECT Toxo IgG, IgM, and IgG Avidity assays for anti-Toxoplasma antibodies detection in pregnant women sera. Diagn. Microbiol. Infect. Dis. 2009, 65:279-287.
14. Liesenfeld O., et al. Confirmatory serologic testing for acute toxoplasmosis and rate of induced abortions among women reported to have positive Toxoplasma immunoglobulin M antibody titers. Am. J. Obstet. Gynecol. 2001, 184:140-145.
15. Garry D.J., et al. Commercial laboratory IgM testing for Toxoplasma gondii in pregnancy: a 20-year experience. Infect. Dis. Obstet. Gynecol. 2005, 13:151-153.
16. Ozerdem D., et al. Comparison of microscopic examination, rK39, and PCR for visceral leishmaniasis diagnosis in Turkey. Parasitol. Res. 2009, 106:197-200.
17. Deborggraeve S., et al. Diagnostic accuracy of a new Leishmania PCR for clinical visceral leishmaniasis in Nepal and its role in diagnosis of disease. Trop. Med. Int. Health 2008, 13:1378-1383.
18. Brun R., et al. Human African trypanosomiasis. Lancet 2010, 375:148-159.
19. Britto C.C. Usefulness of PCR-based assays to assess drug efficacy in Chagas disease chemotherapy: value and limitations. Mem. Inst. Oswaldo Cruz 2009, 104(Suppl 1):122-135.
20. Takagi H., et al. Sensitive, specific, and rapid detection of Leishmania donovani DNA by loop-mediated isothermal amplification. Am. J. Trop. Med. Hyg. 2009, 81:578-582.
21. Rifai N., et al. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol. 2006, 24:971-983.
22. Gao J., et al. Biomarker discovery in biological fluids. Methods 2005, 35:291-302.
23. Hortin G.L. The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin. Chem. 2006, 52:1223-1237.
24. Dea-Ayuela M.A., et al. Proteomic analysis of antigens from Leishmania infantum promastigotes. Proteomics 2006, 6:4187-4194.
25. Potenza M., et al. Analysis of the Trypanosoma cruzi cyclophilin gene family and identification of Cyclosporin A binding proteins. Parasitology 2006, 132:867-882.
26. Wuhrer M., et al. IPSE/alpha-1, a major secretory glycoprotein antigen from schistosome eggs, expresses the Lewis X motif on core-difucosylated N-glycans. FEBS J. 2006, 273:2276-2292.
27. Florens L., et al. A proteomic view of the Plasmodium falciparum life cycle. Nature 2002, 419:520-526.
28. Issaq H.J., et al. The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem. Biophys. Res. Commun. 2002, 292:587-592.
29. Novikova S.I., et al. Identification of protein biomarkers for schizophrenia and bipolar disorder in the postmortem prefrontal cortex using SELDI-TOF-MS ProteinChip profiling combined with MALDI-TOF-PSD-MS analysis. Neurobiol. Dis. 2006, 23:61-76.
30. Ndao M., et al. Identification of novel diagnostic serum biomarkers for Chagas' disease in asymptomatic subjects by mass spectrometric profiling. J. Clin. Microbiol. 2010, 48:1139-1149.
31. Engwegen J.Y., et al. Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. Trends Pharmacol. Sci. 2006, 27:251-259.
32. Bertucci F., et al. Proteomics of breast cancer: principles and potential clinical applications. Mol. Cell. Proteomics. 2006, 5:1772-1786.
33. Rioux M.C., et al. Discovery and validation of serum biomarkers expressed over the first twelve weeks of Fasciola hepatica infection in sheep. Int. J. Parasitol. 2008, 38:123-136.
34. Deckers N., et al. Use of ProteinChip technology for identifying biomarkers of parasitic diseases: the example of porcine cysticercosis (Taenia solium). Exp. Parasitol. 2008, 120:320-329.
35. Vlahou A., et al. Diagnosis of ovarian cancer using decision tree classification of mass spectral data. J. Biomed. Biotechnol. 2003, 2003:308-314.
36. Wilson L.L., et al. Detection of differentially expressed proteins in early-stage melanoma patients using SELDI-TOF mass spectrometry. Ann. N. Y. Acad. Sci. 2004, 1022:317-322.
37. Schmid O., et al. New approaches to identification of bacterial pathogens by surface enhanced laser desorption/ionization time of flight mass spectrometry in concert with artificial neural networks, with special reference to Neisseria gonorrhoeae. J. Med. Microbiol. 2005, 54:1205-1211.
38. Kay R., et al. Enrichment of low molecular weight serum proteins using acetonitrile precipitation for mass spectrometry based proteomic analysis. Rapid Commun. Mass Spectrom. 2008, 22:3255-3260.
39. Caffrey R.E. A review of experimental design best practices for proteomics based biomarker discovery: focus on SELDI-TOF. Methods Mol. Biol. 2010, 641:167-183.
40. Malyarenko D.I., et al. Enhancement of sensitivity and resolution of surface-enhanced laser desorption/ionization time-of-flight mass spectrometric records for serum peptides using time-series analysis techniques. Clin. Chem. 2005, 51:65-74.
41. Marko-Varga G., et al. Discovery of biomarker candidates within disease by protein profiling: principles and concepts. J. Proteome. Res. 2005, 4:1200-1212.
42. Luo X., et al. Macrophage proteomic fingerprinting predicts HIV-1-associated cognitive impairment. Neurology 2003, 60:1931-1937.
43. Schwegler E.E., et al. SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology 2005, 41:634-642.
44. Gobel T., et al. New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples. World J. Gastroenterol. 2006, 12:7604-7612.
45. Nguyen A., Yaffe M.B. Proteomics and systems biology approaches to signal transduction in sepsis. Crit. Care Med. 2003, 31:S1-S6.
46. Papadopoulos M.C., et al. A novel and accurate diagnostic test for human African trypanosomiasis. Lancet 2004, 363:1358-1363.
47. Makawita S., Diamandis E.P. The bottleneck in the cancer biomarker pipeline and protein quantification through mass spectrometry-based approaches: current strategies for candidate verification. Clin. Chem. 2010, 56:212-222.
48. Le B.B., et al. Options for veterinary drug analysis using mass spectrometry. J. Chromatogr. A 2009, 1216:8016-8034.
49. Agranoff D., et al. Proteomic fingerprinting for the diagnosis of human African trypanosomiasis. Trends Parasitol. 2005, 21:154-157.
50. Stiles J.K., et al. Trypanosome apoptotic factor mediates apoptosis in human brain vascular endothelial cells. Mol. Biochem. Parasitol. 2004, 133:229-240.
51. Rai A.J., Vitzthum F. Effects of preanalytical variables on peptide and protein measurements in human serum and plasma: implications for clinical proteomics. Expert. Rev. Proteomics. 2006, 3:409-426.
52. Tammen H., et al. Peptidomic analysis of human blood specimens: comparison between plasma specimens and serum by differential peptide display. Proteomics 2005, 5:3414-3422.
53. Hong H., et al. Quality control and quality assessment of data from surface-enhanced laser desorption/ionization (SELDI) time-of-flight (TOF) mass spectrometry (MS). BMC Bioinformatics 6 Suppl. 2005, 2:S5.
54. Aivado M., et al. Optimization and evaluation of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) with reversed-phase protein arrays for protein profiling. Clin. Chem. Lab. Med. 2005, 43:133-140.
55. Schaub S., et al. Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int. 2004, 65:323-332.
56. Baggerly K.A., et al. Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 2004, 20:777-785.
57. Baggerly K.A., et al. A comprehensive approach to the analysis of matrix-assisted laser desorption/ionization-time of flight proteomics spectra from serum samples. Proteomics 2003, 3:1667-1672.
58. Davis M.T., et al. Cancer biomarker discovery via low molecular weight serum profiling - are we following circular paths?. Clin. Chem. 2010, 56:244-247.
59. Reesink H.W. European strategies against the parasite transfusion risk. Transfus. Clin. Biol. 2005, 12:1-4.
60. Li J., et al. Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin. Chem. 2005, 51:2229-2235.